Recent studies underscore the evolving challenges in heart failure care, influenced by oncology and advanced imaging, as highlighted in a November 2025 review by Dr. Mert Tokcan. Analysis from the Swedish Heart Failure Registry reveals that nearly 20% of heart failure patients have a cancer history, facing increased mortality yet similar hospitalization rates compared to non-malignant patients. Innovations like low-dose sacubitril/valsartan show potential in preventing therapy-related cardiac dysfunction. Emphasizing multidisciplinary care may enhance outcomes across various heart failure scenarios.
1. 20% of heart failure patients have cancer history. 2. Higher mortality yet similar hospitalization rates for these patients. 3. Importance of multidisciplinary care emphasized. 4. Sacubitril/Valsartan shows promise in cardiac dysfunction prevention. 5. Echo features indicate cardiac wasting in advanced cancer. 6. High-volume centers linked with lower mortality in cardiogenic shock. 7. Need for large multicenter trials to confirm findings.
Listen Tab content
